Tetraphase Pharmaceuticals (NASDAQ:TTPH) and ImmunoGen (NASDAQ:IMGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.
This table compares Tetraphase Pharmaceuticals and ImmunoGen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings for Tetraphase Pharmaceuticals and ImmunoGen, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Tetraphase Pharmaceuticals presently has a consensus target price of $6.57, suggesting a potential upside of 212.93%. ImmunoGen has a consensus target price of $14.75, suggesting a potential upside of 150.42%. Given Tetraphase Pharmaceuticals’ higher probable upside, equities research analysts clearly believe Tetraphase Pharmaceuticals is more favorable than ImmunoGen.
Volatility and Risk
Tetraphase Pharmaceuticals has a beta of 2.57, meaning that its stock price is 157% more volatile than the S&P 500. Comparatively, ImmunoGen has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500.
Institutional and Insider Ownership
40.9% of Tetraphase Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.8% of ImmunoGen shares are owned by institutional investors. 4.1% of Tetraphase Pharmaceuticals shares are owned by insiders. Comparatively, 4.4% of ImmunoGen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Tetraphase Pharmaceuticals and ImmunoGen’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Tetraphase Pharmaceuticals||$9.67 million||11.48||-$114.75 million||($2.63)||-0.80|
|ImmunoGen||$115.45 million||7.60||-$96.01 million||($0.75)||-7.85|
ImmunoGen has higher revenue and earnings than Tetraphase Pharmaceuticals. ImmunoGen is trading at a lower price-to-earnings ratio than Tetraphase Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ImmunoGen beats Tetraphase Pharmaceuticals on 8 of the 11 factors compared between the two stocks.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with eravacycline through investigating Gram-negative infections treated with eravacycline (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize eravacycline for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.
ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.